<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108146</url>
  </required_header>
  <id_info>
    <org_study_id>HPA-PTSD-1</org_study_id>
    <nct_id>NCT01108146</nct_id>
  </id_info>
  <brief_title>Hydrocortisone in the Treatment of Intrusions in Patients With Posttraumatic Stress Disorder</brief_title>
  <official_title>Monocentric, Double-blind Placebo-Controlled, Randomized Cross-Sectional Clinical Trial of Hydrocortisone (10 and 30 mg/d) in Outpatients With Posttraumatic-Stress-Disorder (PTSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test overall efficacy of hydrocortisone on reexperience of traumatic memories (intrusions)
      and overall symptomatology in patients meeting criteria of complex chronic PTSD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of the frequency and intensity of intrusions assessed with the subscale Intrusions of the Impact of Event Scale (IES-R)</measure>
    <time_frame>4 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of the overall PTSD symptomatology assessed with the IES-R and the Posttraumatic Diagnostic Scale (PDS)</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Hydrocortisone 10 mg
Group 1: Administration of Hydrocortisone and/or Placebo in the following order:
1 week placebo-1 week hydrocortisone 10 mg/d -1 week placebo - 1 week hydrocortisone 30 mg/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Hydrocortisone 30 mg
Group 2: Administration of Hydrocortisone and/or Placebo in the following order:
1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 1 Hydrocortisone 10 mg</intervention_name>
    <description>Group 1: Administration of Hydrocortisone and/or Placebo in the following order:
1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm 2 Hydrocortisone 30 mg</intervention_name>
    <description>Drug: Hydrocortisone 30 mg
Group 2: Administration of Hydrocortisone and/or Placebo in the following order:
1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written Informed Consent

          -  Female patients with PTSD according to DSM-IV criteria (see Appendix 2).

          -  18-45 years

          -  Intrusions (according to IES-R subscale Intrusions: Value: &gt; 7

          -  Ability of subject to understand character and individual consequences of the clinical
             trial

          -  No participation in another clinical trial (up from 30 days before this trial)

        Exclusion Criteria:

          -  Lifetime diagnosis schizophrenia according to DSM-IV

          -  Mental retardation

          -  Body mass index &lt; 16.5

          -  Current drug and alcohol abuse and addiction

          -  Life-threatening self-injurious behavior in the last 4 months

          -  Suicide attempt with the strong intention to die in the last 4 months.

          -  Following diseases in anamnesis: stomach ulcera or intestinal ulcera, pancreatitis,
             corticoid-induced psychosis, severe osteoporosis, severe hyper-tension, heart failure,
             myasthenia gravis, asthma bronchiale, glaucoma, cataract, diabetes mellitus, herpes
             simples, herpes zoster (viremic phase), renal transplantation.

          -  Any pretreatment with hydrocortisone in the last 4 weeks prior to the first
             administration of Investiga-tional Medicinal Product.

          -  Following current medication: cardiac glycosides, saluretics, antidiabetics,
             cumarin-derivatives, rifampicine, phenytoine, barbiturates, primidone, NSAID,
             salicylate and indometacine, atropine, praziquantel, chloroquine, hydroxychloroquine,
             mefloquine, somatropine, protireline, cyclosporine, non-depolarising muscle relaxants.

          -  Pregnancy or lactation period

          -  Inadequate birth control (Adequate birth control: implants, injectables, combined oral
             contraceptives, intrauterine devices (IUDs), sexual abstinence or vasectomised
             partner)

          -  Shift working

          -  Intercontinental travel within 2 weeks prior to enrollment (to avoid jet-lag)

          -  History of hypersensitivity to investigational medicinal product or to any drug with
             similar chemical structure or to any excipient present in the pharmaceutical form of
             the investigational medicinal product.

          -  No subject will be allowed to enrol in this trial more than once.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Schmahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Insitute of Mental Health, Dpt. of Psychosomatic and Psychotherapeutic Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Institute of Mental Health, Dpt. of Psychosomatic and Psychotherapeutic Medicine</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Institute of Mental Health, Mannheim</investigator_affiliation>
    <investigator_full_name>Petra Ludaescher</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

